Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Nira Hadar"'
Autor:
Umberto Vitolo, Grzegorz S. Nowakowski, John M. Burke, Christopher P. Fox, Marek Trneny, Annalisa Chiappella, Maeve Waldron-Lynch, Nira Hadar, Alok Pachori, Georg Lenz
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:S352-S353
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0775c62d16c9311f5e0b1977217da56e
https://doi.org/10.1016/s2152-2650(22)01488-4
https://doi.org/10.1016/s2152-2650(22)01488-4
Autor:
Umberto Vitolo, Grzegorz S. Nowakowski, John M. Burke, Christopher P. Fox, Marek Trneny, Annalisa Chiappella, Maeve Waldron-Lynch, Nira Hadar, Alok Pachori, Georg Lenz
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:S163
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::21854a494885c0a1af287c425885d38f
https://doi.org/10.1016/s2152-2650(22)00999-5
https://doi.org/10.1016/s2152-2650(22)00999-5
Autor:
David Belada, Katerina Kopeckova, Juan Miguel Bergua Burgues, Don Stevens, Grzegorz S. Nowakowski, Maeve Waldron-Lynch, Nira Hadar, Johannes Weirather, Charlotte Lässig, Derek Blair, Martin Dreyling
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:S352
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5fbff6f8967febe93f78c2f2d2dd7d90
https://doi.org/10.1016/s2152-2650(22)01487-2
https://doi.org/10.1016/s2152-2650(22)01487-2
Autor:
Jill Buck, Yunxia Wang, Nira Hadar, Laurence J.N. Cooper, Nathan Demars, John Miao, John Loewy, John S. Yu, Nancy Ann Oberheim Bush, Rimas V. Lukas, Joseph Landolfi, Arnold Gelb, Robert Cavaliere, Sylvia Kurz, E. Antonio Chiocca
Publikováno v:
Neuro Oncol
Ad-RTS-hIL-12 (Ad) is a gene therapy candidate for intratumoral (IT) delivery that conditionally expresses IL-12 (IL-12) under the transcriptional control of orally administered veledimex (V) acting via the RheoSwitch Therapeutic Systemâ gene switch
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28c81a9468f41bd3331cc06fa6cc0f2f
https://europepmc.org/articles/PMC7650356/
https://europepmc.org/articles/PMC7650356/
Autor:
Nate Demars, John S. Yu, Kamal Chadha, John Loewy, Nancy Ann Oberheim-Bush, Rimas V. Lukas, Christina Amidei, Jill Buck, Nira Hadar, Taylor Estupinan, Laurence J.N. Cooper, Robert Cavaliere, E. Antonio Chiocca, Christine Cordova, Clark C. Chen, Joseph Landolfi, John Miao
Publikováno v:
Neuro Oncol
Ad-RTS-hIL-12(Ad) is a gene therapy candidate conditionally expressing IL-12 under the transcriptional control of veledimex(V) acting via the RheoSwitch Therapeutic System® gene switch. Veledimex plasma and tumor PK demonstrated a dose-response rela
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5df2902ca8cc3260adc608af80a09d62
https://doi.org/10.1093/neuonc/noab196.212
https://doi.org/10.1093/neuonc/noab196.212
Autor:
Laurence J.N. Cooper, Erin Walsh, John Miao, Arnold Gelb, Sabine Mueller, Rudy Allen, Amanda Saratsis, Nira Hadar, Stewart Goldman, Taylor Estupinan, Jill Buck, Nathan Demars, Susan N. Chi
Publikováno v:
Neuro Oncol
DIPG, which is the leading cause of pediatric brain cancer death with no effective treatment, has neither a highly immunosuppressive nor inflammatory tumor microenvironment (TME). Therefore, eliciting a pro-inflammatory TME may provide therapeutic be
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b922cb7fbd95e5af309ec3ff329fb1d3
https://doi.org/10.1093/neuonc/noaa215.161
https://doi.org/10.1093/neuonc/noaa215.161
Autor:
Yunxia Wang, Taylor Estupinan, Rimas V. Lukas, Christina Amidei, John Loewy, Nathan Demars, Jill Buck, Arnold Gelb, Ganesh Rao, Nira Hadar, E. Antonio Chiocca, Laurence J.N. Cooper, John Miao, Clark C. Chen
Publikováno v:
Neuro Oncol
A published clinical trial of veledimex (V)-regulatable interleukin-12 (IL-12) gene therapy (“Controlled IL-12”) under the control of a transcriptional switch (RheoSwitch Therapeutic Systemâ, RTSâ) as monotherapy in recurrent glioblastoma (rGBM
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a6ad45959813348722590797be296b9
https://doi.org/10.1093/neuonc/noaa215.139
https://doi.org/10.1093/neuonc/noaa215.139
Autor:
John Loewy, Christina Amidei, Jill Buck, E. Antonio Chiocca, John S. Yu, Yunxia Wang, Nira Hadar, Arnold Gelb, Nathan Demars, Bakhtiar Yamini, Nancy Ann Oberheim Bush, Rimas V. Lukas, Taylor Estupinan, Laurence J.N. Cooper, John Miao
Publikováno v:
Journal of Clinical Oncology. 38:3040-3040
3040 Background: Interleukin-12 (IL-12), a master regulator of the immune system, results in anti-tumor responses in preclinical models, but safe use requires tightly controlled production. This phase 1 trial (NCT02026271) is the first to evaluate th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f82b7c1eb8f55e95c81e1f653596eff5
https://doi.org/10.1200/jco.2020.38.15_suppl.3040
https://doi.org/10.1200/jco.2020.38.15_suppl.3040
Autor:
Nira Hadar, Arnold Gelb, Laurence J.N. Cooper, John Miao, E. Antonio Chiocca, John Loewy, Rimas V. Lukas, Christina Amidei, Taylor Estupinan, Jill Buck, Yunxia Wang, Nathan Demars, Ganesh Rao, Clark C. Chen
Publikováno v:
Journal of Clinical Oncology. 38:2510-2510
2510 Background: Monotherapy with intratumoral Ad-RTS-hIL-12 (Ad), a gene therapeutic conditionally expressing IL-12 under the transcriptional control of oral veledimex (“Controlled IL-12”), was shown in a phase 1 study (NCT02026271) to elicit a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bf9416ac8d75cf9fc62599ba33f9a4a7
https://doi.org/10.1200/jco.2020.38.15_suppl.2510
https://doi.org/10.1200/jco.2020.38.15_suppl.2510
Autor:
Ganesh Rao, Sylvia Kurz, Yunxia Wang, Christina Amidei, Taylor Estupinan, Nathan Demars, Joseph Landolfi, Rimas V. Lukas, John S. Yu, Laurence J.N. Cooper, John Miao, Arnold Gelb, Jill Buck, John Loewy, Nira Hadar
Publikováno v:
Journal of Clinical Oncology. 38:2564-2564
2564 Background: Interleukin-12 (IL-12) results in anti-tumor responses in preclinical models but requires tightly controlled production to achieve safety and elicit immune system activation to realize efficacy. A phase 1 “main study” (NCT0202627
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a7bcce6e93674a66f16531f20754da43
https://doi.org/10.1200/jco.2020.38.15_suppl.2564
https://doi.org/10.1200/jco.2020.38.15_suppl.2564